




RealRate

PHARMACEUTICAL 2017

Supernus Pharmaceuticals INC
Rank 86 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 328%, being 83% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	151,404
Cost of Goods Sold	0
Intangible Assets	16,490
Liabilities, Current	80,742
Liabilities, Non-Current	4,002
Other Assets	137,330
Other Compr. Net Income	354
Other Expenses	-28,866
Other Liabilities	33,069
Other Net Income	-3,847
Other Revenues	215,003
Property and Equipment	4,344
Research and Development	42,791
Selling, General and Administrative Expense	106,010

Output Variable	Value in 1000 USD
Assets	309,568
Liabilities	117,813
Expenses	119,935
Revenues	215,003
Stockholders Equity	191,755
Net Income	91,221
Comprehensive Net Income	91,398
BaseVar	383,260
ECR before LimitedLiability	238%
Economic Capital Ratio	328%